It’s Not “One Size Fits All”: Addressing Complications and Barriers to Unlock Individualized Treatment and Management for Patients with Hemophilia A
Brought to you by:
AKH and Catalyst
Series Courses
Hemophilia A is an inherited bleeding disorder due to the partial or total deficiency of coagulation factor VIII (FVIII). Remarkable progress has been made in hemophilia therapy over the last decades with the development of efficacious therapies and extended half-life products, based on prophylactic replacement of FVIII and an improved understanding of the management of inhibitory antibodies to infused factor and the potential for gene therapy as a therapeutic option.

These activities will review the management of hemophilia A and examine the role of current and emerging therapeutic recommendations. Case vignettes will be presented to highlight the role of the hematology care team in the management of hemophilia A and the importance of using shared decision-making strategies to help patients and/or caregivers adhere to treatment plans.

AKH-logo-11-22-21.jpg       Catalyst_Logo